nach oben

Clinical Rheumatology

Erschienen in:

26.07.2022 | Original Article

Role of macrophage-associated chemokines in the assessment of initial axial spondyloarthritis

verfasst von: Xuegang Li, Anqi Liang, Yujie Cui, Juan Liao, Xueling Fang, Shuping Zhong

Erschienen in: Clinical Rheumatology | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To identify biomarkers that reflect disease activity scores and to investigate the role of macrophage-associated chemokines in initial axial spondyloarthritis (axSpA).

Method

Patients with axSpA were enrolled. The SpondyloArthritis Research Consortium of Canada (SPARCC) method was used to score bone marrow oedema (BMO) in the inflammatory lesions on magnetic resonance imaging (MRI). Radiographic assessment of the spine was performed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Clinical variables, including inflammatory markers, serum CC chemokine ligand 2 (CCL2), CCL3, CCL7, CCL8 and C-X3-C motif ligand 1 (CX3CL1), were measured. Correlation analysis between serum levels of these macrophage-associated chemokines and clinical data was performed.

Results

There were no significant differences between the axSpA group and the healthy control group in terms of serum levels of CCL2, CCL3 or CCL8. Compared to the healthy control group, the serum levels of CCL7 and CX3CL1 were significantly higher in ankylosing spondylitis (AS) (p = 0.045, p = 0.017, respectively). In the AS subgroup, the serum level of CX3CL1 had a positive correlation with SPARCC scores.

Conclusions

In AS, serum CCL7 and CX3CL1 levels are elevated. The serum level of CX3CL1 is associated with MRI-determined oedema in AS. CX3CL1 may be useful as a biomarker to predict active inflammation in the sacroiliac joint (SIJ) in AS.

Key Points

• Serum levels of CX3CL1 are associated with MRI-determined oedema in AS.

• CX3CL1 may be a useful biomarker to predict active inflammation in the sacroiliac joint in AS.

Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127–2137. https://doi.org/10.1016/S0140-6736(11)60071-8CrossRefPubMed

Rudwaleit M, Landewé R, van der Heijde D et al (2009) The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68:770–776. https://doi.org/10.1136/ard.2009.108217CrossRefPubMed

Bowness P (2015) HLA-B27. Annu Rev Immunol 33:29–48. https://doi.org/10.1146/annurev-immunol-032414-112110CrossRefPubMed

Trull A, Ebringer A, Panayi G et al (1984) HLA-B27 and the immune response to enterobacterial antigens in ankylosing spondylitis. Clin Exp Immunol 55:74–80PubMedPubMedCentral

Madej M, Nowak B, Świerkot J et al (2015) Cytokine profiles in axial spondyloarthritis. Reumatologia 53:9–13. https://doi.org/10.5114/reum.2015.50551CrossRefPubMedPubMedCentral

Sveaas SH, Berg IJ, Provan SA et al (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44:118–124. https://doi.org/10.3109/03009742.2014.956142CrossRefPubMed

Ward MM, Deodhar A, Gensler LS et al (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken) 71:1285–1299. https://doi.org/10.1002/acr.24025CrossRef

Baeten D, Kruithof E, De Rycke L et al (2005) Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 7:359–369. https://doi.org/10.1186/ar1501CrossRef

Bresnihan B, Pontifex E, Thurlings RM et al (2009) Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol 36:1800–1802. https://doi.org/10.3899/jrheum.090348CrossRefPubMed

10.

Vanaki N, Aslani S, Jamshidi A et al (2018) Role of innate immune system in the pathogenesis of ankylosing spondylitis. Biomed Pharmacother 15:130–143. https://doi.org/10.1016/j.biopha.2018.05.097CrossRef

11.

van der Linden S, Valkenburg HA, Cats A et al (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368. https://doi.org/10.1002/art.1780270401CrossRefPubMed

12.

Lukas C, Landewé R, Sieper J et al (2008) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24. https://doi.org/10.1136/ard.2008.094870CrossRefPubMed

13.

Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed

14.

Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed

15.

Maksymowych WP, Inman RD, Salonen D et al (2005) Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 53:703–709. https://doi.org/10.1002/art.21445CrossRefPubMed

16.

Creemers MC, Franssen MJ, van’t Hof MA et al (2005) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64:127–129. https://doi.org/10.1136/ard.2004.020503CrossRefPubMed

17.

Nanki T, Imai T, Kawai S et al (2017) Fractalkine/CX3CL1 in rheumatoid arthritis. Mod Rheumatol 27:392–397. https://doi.org/10.1080/14397595.2016.1213481CrossRefPubMed

18.

Umemura M, Isozaki T, Ishii S et al (2014) Reduction of serum ADAM17 level accompanied with decreased cytokines after abatacept therapy in patients with rheumatoid arthritis. Int J Biomed Sci 10:229–235PubMedPubMedCentral

19.

Ciccia F, Alessandro R, Rizzo A et al (2014) Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis. Rheumatology (Oxford) 53:104–113. https://doi.org/10.1093/rheumatology/ket323CrossRef

20.

McGonagle D, Marzo-Ortega H, O’Connor et al (2002) Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 61:534–537. https://doi.org/10.1136/ard.61.6.534CrossRefPubMedPubMedCentral

21.

Bollow M, Fischer T, Reisshauer H et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59:135–140. https://doi.org/10.1136/ard.59.2.135CrossRefPubMedPubMedCentral

22.

Wang X, Xia S, Fu B (2014) RNA-seq analysis of synovial fibroblasts in human rheumatoid arthritis. Mol Med Rep 10:241–247. https://doi.org/10.3892/mmr.2014.2182CrossRefPubMed

23.

Ruth JH, Volin MV, Haines GK et al (2001) Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 44:1568–1581. https://doi.org/10.1002/1529-0131(200107)44:7%3c1568::AID-ART280%3e3.0.CO;2-1CrossRefPubMed

24.

Ciccia F, Guggino G, Zeng M et al (2018) Pro-inflammatory CX3CR1+CD59+TL1A+IL-23+ monocytes are expanded in patients with ankylosing spondylitis and modulate ILC3 immune functions. Arthritis Rheumatol 70:2003–2013. https://doi.org/10.1002/art.40582CrossRefPubMed

25.

Ciccia F, Guggino G, Rizzo A et al (2015) Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis 74:1739–1747. https://doi.org/10.1136/annrheumdis-2014-206323CrossRefPubMed

26.

Staniland AA, Clark AK, Wodarski R et al (2010) Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 114:1143–1157. https://doi.org/10.1111/j.1471-4159.2010.06837.xCrossRefPubMed

27.

Matsuura T, Ichinose S, Akiyama M et al (2017) Involvement of CX3CL1 in the migration of osteoclast precursors across osteoblast layer stimulated by interleukin-1β. J Cell Physiol 232:1739–1745. https://doi.org/10.1002/jcp.25577CrossRefPubMed

28.

Koizumi K, Saitoh Y, Minami T et al (2009) Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol 183:7825–7831. https://doi.org/10.4049/jimmunol.0803627CrossRefPubMed

29.

Pishgahi A, Abolhasan R, Danaii S et al (2020) Immunological and oxidative stress biomarkers in ankylosing spondylitis patients with or without metabolic syndrome. Cytokine 128:155002. https://doi.org/10.1016/j.cyto.2020.155002CrossRefPubMed

Titel: Role of macrophage-associated chemokines in the assessment of initial axial spondyloarthritis
verfasst von: Xuegang Li
Anqi Liang
Yujie Cui
Juan Liao
Xueling Fang
Shuping Zhong
Publikationsdatum: 26.07.2022
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 11/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-022-06308-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objectives

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study

Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients

Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone

The clinical pattern differentiates ANCA-positive infective endocarditis patients from ANCA-associated vasculitis patients: a 23 years’ retrospective cohort study in China and follow-ups

Clinical characteristics and outcomes of digital gangrene in connective tissue disorders: a longitudinal single-centre experience from Jodhpur, India